| __timestamp | Catalent, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 5078000000 |
| Thursday, January 1, 2015 | 337300000 | 4717000000 |
| Friday, January 1, 2016 | 358100000 | 5096000000 |
| Sunday, January 1, 2017 | 402600000 | 4986000000 |
| Monday, January 1, 2018 | 462600000 | 4214000000 |
| Tuesday, January 1, 2019 | 512000000 | 3806000000 |
| Wednesday, January 1, 2020 | 577900000 | 3671000000 |
| Friday, January 1, 2021 | 687000000 | 3528000000 |
| Saturday, January 1, 2022 | 844000000 | 3445000000 |
| Sunday, January 1, 2023 | 831000000 | 3498000000 |
| Monday, January 1, 2024 | 935000000 | 3702000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Catalent, Inc. over the past decade. From 2014 to 2023, Teva's SG&A expenses have shown a downward trend, decreasing by approximately 31% from 2014 to 2023. In contrast, Catalent's expenses have surged by nearly 148% during the same period, reflecting its aggressive expansion strategy.
Teva's peak in 2016, with expenses reaching over 5 billion, contrasts sharply with Catalent's steady climb, culminating in 2023 with expenses nearing 935 million. This divergence highlights differing strategic priorities: Teva's focus on cost optimization versus Catalent's investment in growth. Notably, data for Teva in 2024 is unavailable, indicating potential reporting delays or strategic shifts.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Bristol-Myers Squibb Company or Catalent, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited and United Therapeutics Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Catalent, Inc. or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc